Bivalirudin versus heparin in STEMI after BRIGHT-4 trial: an updated meta-analysis
Updated meta-analysis published in Coronary Artery Disease (2023)
Abstract
BACKGROUND: The use of bivalirudin-based anticoagulation over heparin-based anticoagulation for coronary percutaneous intervention has been debated for a long time. Multiple trials have shown promising benefits of bivalirudin over heparin therapy with the most recent addition being the BRIGHT-4 trial. We performed a meta-analysis to assess evidence from these trials, focusing on the coronary intervention of the STEMI population. METHODS: This meta-analysis was performed based on PRISMA guidelines after registering in PROSPERO (CRD42023394701). Databases were searched for relevant articles published before January 2023. Pertinent data from the included studies were extracted and analyzed using RevMan v5.4. RESULTS: Out of 2375 studies evaluated, 13 randomized control trials with 24 360 acute ST-elevation myocardial infarction patients were included for analysis. The bivalirudin-based anticoagulation reduced the net clinical events (OR 0.75, CI 0.61-0.92), major adverse cardiac or cerebral events (OR 0.85, CI 0.74-0.98), any bleeding (OR 0.61, CI 0.45-0.83), major bleeding (OR 0.54, CI 0.39-0.75), all-cause mortality (OR 0.79, CI 0.67-0.92) and cardiac mortality (OR 0.78, CI 0.65-0.93) significantly without increasing the risk of any stent thrombosis (OR 0.92, 95% CI 0.52-1.61), definite stent thrombosis (OR 1.17, 95% CI 0.62-2.22) and acute stent thrombosis (OR 2.06, 95% CI 0.69-6.09) significantly at 30 days. CONCLUSION: Based on this meta-analysis, bivalirudin plus a post-PCI high-dose infusion-based anticoagulation during STEMI PCI has significant benefits over heparin therapy for cardiovascular outcomes without a significant increase in the risk of thrombotic outcomes.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Updated post-BRIGHT-4 STEMI meta-analysis confirming bivalirudin reduces 30-day all-cause mortality and major bleeding in primary PCI versus heparin.
Por qué esto importa para la hirudoterapia
Este metaanálisis actualizado de 13 ensayos controlados aleatorizados (24.360 pacientes con IAMCEST) encontró que la anticoagulación basada en bivalirudina durante la intervención coronaria percutánea redujo significativamente los eventos clínicos netos, el sangrado mayor, la mortalidad por todas las causas y la mortalidad cardíaca a 30 días frente a la heparina, sin aumentar significativamente la trombosis del stent. La bivalirudina es un inhibidor directo sintético de la trombina modelado a partir de la hirudina, el anticoagulante presente en la saliva de la sanguijuela medicinal, por lo que esta evidencia cardiovascular a gran escala es directamente informativa para la ciencia del secretoma de la sanguijuela e ilustra cómo un principio farmacológico derivado de la sanguijuela se traduce en la cardiología clínica convencional. Para la ASH, estos hallazgos aportan datos contemporáneos de desenlaces sobre un análogo de la hirudina ampliamente utilizado en medicina intervencionista. Sin embargo, el estudio evalúa un derivado farmacéutico más que la hirudoterapia con sanguijuelas vivas o el secretoma completo de la sanguijuela, y los resultados se limitan a desenlaces a corto plazo de 30 días en una población cardíaca específica.
Citación
Bivalirudin versus heparin in STEMI after BRIGHT-4 trial: an updated meta-analysis.
Oli PR et al. · Coronary artery disease, 2023
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026